UNSPSC 51241503: Antipyrine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.

UNSPSC 51241503 Antipyrine/phenylephrine, a Commodity code, covers generic multi-source pharmaceuticals and over-the-counter products that state and local government health facilities, correctional systems, and public health agencies procure through cooperative purchasing vehicles and direct solicitations. The code encompasses finished pharmaceutical products identified by National Drug Code (NDC), with vendors supplying through authorized wholesalers rather than direct to end-use facilities. State and local issuing bodies under this code include state health departments, corrections agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions to negotiate volume pricing and standardized product availability.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The solicitation covers participating state and local government facilities including Oregon, with awarded vendors required to supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation is weighted heavily toward price competitiveness (75 percent), with the remainder addressing fixed pricing (10 percent), compliance with administrative data-format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract term runs two years from July 1, 2026 with optional extensions, and vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, along with cGMP and Drug Supply Chain Security Act (DSCSA) compliance.